Table 2 Clinical results in the four groups
| Â | Group 1: Donor and recipient non-marginal | Group 2: Donor non- marginal, recipient marginal | Group 3: Donor marginal, recipient non-marginal | Group 4: Donor and recipient marginal | P -value |
|---|---|---|---|---|---|
No. of patients | 138 | 41 | 69 | 84 | - |
Duration of surgery (minutes) | 159 ± 63 | 164 ± 63 | 153 ± 41 | 173 ± 71 | 0.358 |
Immunosuppression | Â | Â | Â | Â | Â |
Mycophenolate mofetil (Cell Cept) | 101 (73%) | 24 (59%) | 44 (64%) | 53 (63%) | 0.203 |
Tacrolimus | 86 (62%) | 22 (54%) | 37 (54%) | 49 (58%) | 0.593 |
Cyclosporin A | 44 (32%) | 18 (44%) | 25 (36%) | 30 (36%) | 0.559 |
Sirolimus | 5 (4%) | 1 (2%) | 11 (16%) | 4 (5%) | 0.003 |
Intensive care stay donor (days) | 6.2 ± 5.7 | 6.9 ± 6.6 | 6.1 ± 6.0 | 3.5 ± 3.2 | 0.001§ |
Hospital stay recipient (days) | 18.0 ± 14.0 | 18.9 ± 14.2 | 15.7 ± 11.6 | 17.7 ± 19.5 | 0.699 |
Any complication * | 48 (36%) | 20 (49%) | 36 (52%) | 36 (43%) | 0.151 |
Rejection | 38 (28%) | 2 (5%) | 27 (39%) | 26 (31%) | 0.001 |
Primary non-function requiring dialysis | 50 (38%) | 11 (27%) | 20 (29%) | 32 (39%) | 0.355 |
Loss of graft | 8 (6%) | 2 (5%) | 7 (10%) | 8 (10%) | 0.539 |
Death | 3 (2%) | 2 (5%) | 1 (1%) | 6 (7%) | 0.176 |